Which mRCC patients should receive a TKI
Primo N. Lara, Jr., MD, explains how he decides which metastatic renal cell carcinoma (mRCC) patients should receive a TKI as 1st line therapy
Author: obr
Added: 07/23/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts